Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 2
1(50.0%)
2Total
N/A(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03527719Not ApplicableActive Not Recruiting

China Rural Hypertension Control Project

Role: collaborator

NCT05244993Phase 2Unknown

AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer

Role: collaborator

NCT04433403Unknown

Pathogenic Microorganisms in Adult Severe Pneumonia Patients

Role: collaborator

NCT05001321Unknown

Multi-center and Multi-modal Deep Learning Study of Gastric Cancer

Role: collaborator

All 4 trials loaded